Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence

Safinamide (Xadago(®)) is a novel medication with both dopaminergic and non-dopaminergic effects, approved first by the European Commission and more recently by the US Food and Drug Administration (FDA) as an adjunctive treatment to carbidopa/levodopa in patients with mid- to late-stage Parkinson’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bette, Sagari, Shpiner, Danielle S, Singer, Carlos, Moore, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152599/
https://www.ncbi.nlm.nih.gov/pubmed/30271159
http://dx.doi.org/10.2147/TCRM.S139545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152599/
https://www.ncbi.nlm.nih.gov/pubmed/30271159
http://dx.doi.org/10.2147/TCRM.S139545

Ejemplares similares